Home / Products / Polyclonal antibody /

Product code: YP-Ab-00781
Promotional price:

Product introduction

Reactive species
Human;Rat;Mouse;
Applications
WB; ELISA
Antibody type
Polyclonal Antibody
Gene Name
LPA
Protein name
APOA
Dalton(DA)
Immunogen
Synthesized peptide derived from human APOA
Specificity
This antibody detects endogenous levels of Human APOA
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source
Polyclonal, Rabbit,IgG
Dilution rate
WB 1:1000-2000 ELISA 1:5000-20000
Purification process
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
Concentration
1 mg/ml
Stockpile
-20°C/1 year
Other name
Apolipoprotein(a;Apo(a);Lp(a);EC 3.4.21.-)
Background
The protein encoded by this gene is a serine proteinase that inhibits the activity of tissue-type plasminogen activator I. The encoded protein constitutes a substantial portion of lipoprotein(a) and is proteolytically cleaved, resulting in fragments that attach to atherosclerotic lesions and promote thrombogenesis. Elevated plasma levels of this protein are linked to atherosclerosis. Depending on the individual, the encoded protein contains 2-43 copies of kringle-type domains. The allele represented here contains 15 copies of the kringle-type repeats and corresponds to that found in the reference genome sequence. [provided by RefSeq, Dec 2009],
Function
disease:Elevated plasma concentrations of apo(a) and its naturally occurring proteolytic fragments are correlated with atherosclerosis. Homology with plasminogen kringles IV and V is thought to underlie the atherogenicity of the protein, because the fragments are competing with plasminogen for fibrin(ogen) binding.,function:Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330.,miscellaneous:Apo(a) is known to be proteolytically cleaved, leading to the formation of the so-called mini-Lp(a). Apo(a) fragments accumulate in atherosclerotic lesions, where they may promote thrombogenesis. O-glycosylation may limit the extent of proteolytic fragmentation.,online information:The Singapore human mutation and polymorphism database,polymorphis

Open

Product Details

Customer data and reviews (0)

Fold content

Citation (0)

Fold content

Experimental scheme

Fold content
>